Tower Research Capital (TRC)’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-6,527
| Closed | -$837K | – | 5238 |
|
|
2025
Q2 | $837K | Sell |
6,527
-1,648
| -20% | -$171K | 0.02% | 636 |
|
|
2025
Q1 | $711K | Buy |
8,175
+910
| +13% | +$88.8K | 0.02% | 659 |
|
|
2024
Q4 | $634K | Buy |
7,265
+6,541
| +903% | +$599K | 0.01% | 909 |
|
|
2024
Q3 | $67K | Sell |
724
-10,390
| -93% | -$1.03M | ﹤0.01% | 2548 |
|
|
2024
Q2 | $1.2M | Buy |
11,114
+8,443
| +316% | +$845K | 0.02% | 657 |
|
|
2024
Q1 | $253K | Sell |
2,671
-4,699
| -64% | -$403K | 0.01% | 1265 |
|
|
2023
Q4 | $680K | Buy |
7,370
+6,437
| +690% | +$417K | 0.01% | 1135 |
|
|
2023
Q3 | $46.9K | Sell |
933
-6,239
| -87% | -$333K | ﹤0.01% | 2599 |
|
|
2023
Q2 | $453K | Buy |
7,172
+4,899
| +216% | +$266K | 0.02% | 1045 |
|
|
2023
Q1 | $102K | Buy |
2,273
+1,254
| +123% | +$56.5K | ﹤0.01% | 1847 |
|
|
2022
Q4 | $45K | Sell |
1,019
-10,174
| -91% | -$488K | ﹤0.01% | 2428 |
|
|
2022
Q3 | $737K | Sell |
11,193
-4,486
| -29% | -$288K | 0.01% | 860 |
|
|
2022
Q2 | $792K | Buy |
15,679
+14,514
| +1,246% | +$850K | 0.02% | 833 |
|
|
2022
Q1 | $75K | Sell |
1,165
-1,543
| -57% | -$111K | ﹤0.01% | 2405 |
|
|
2021
Q4 | $290K | Buy |
2,708
+24
| +0.9% | +$2.51K | 0.01% | 1501 |
|
|
2021
Q3 | $276K | Sell |
2,684
-34
| -1% | -$3.17K | 0.01% | 1496 |
|
|
2021
Q2 | $239K | Sell |
2,718
-3,375
| -55% | -$309K | 0.01% | 1784 |
|
|
2021
Q1 | $593K | Buy |
6,093
+2,106
| +53% | +$210K | 0.01% | 1096 |
|
|
2020
Q4 | $447K | Sell |
3,987
-1,922
| -33% | -$203K | 0.01% | 1079 |
|
|
2020
Q3 | $547K | Sell |
5,909
-588
| -9% | -$45.3K | 0.01% | 1581 |
|
|
2020
Q2 | $507K | Buy |
+6,497
| New | +$439K | 0.02% | 1025 |
|
|
2020
Q1 | – | Sell |
-4,906
| Closed | -$393K | – | 3075 |
|
|
2019
Q4 | $393K | Buy |
4,906
+4,851
| +8,820% | +$363K | 0.03% | 354 |
|
|
2019
Q3 | $4K | Buy |
55
+28
| +104% | +$2.42K | ﹤0.01% | 3390 |
|
|
2019
Q2 | $3K | Buy |
27
+1
| +4% | +$83 | ﹤0.01% | 3113 |
|
|
2019
Q1 | $2K | Buy |
+26
| New | +$1.92K | ﹤0.01% | 3382 |
|
|
2018
Q4 | – | Sell |
-127
| Closed | -$10K | – | 3832 |
|
|
2018
Q3 | $10K | Buy |
127
+119
| +1,488% | +$8.27K | ﹤0.01% | 2746 |
|
|
2018
Q2 | $1K | Buy |
+8
| New | +$637 | ﹤0.01% | 3456 |
|
|
2018
Q1 | – | Sell |
-2,513
| Closed | -$190K | – | 3272 |
|
|
2017
Q4 | $190K | Buy |
2,513
+2,272
| +943% | +$160K | 0.02% | 574 |
|
|
2017
Q3 | $17K | Buy |
+241
| New | +$12.9K | ﹤0.01% | 2816 |
|
|
2017
Q1 | – | Sell |
-158
| Closed | -$4K | – | 3090 |
|
|
2016
Q4 | $4K | Buy |
+158
| New | +$4.76K | ﹤0.01% | 3128 |
|
|
2016
Q2 | – | Sell |
-1,535
| Closed | -$28K | – | 4438 |
|
|
2016
Q1 | $28K | Buy |
+1,535
| New | +$26.6K | ﹤0.01% | 1107 |
|
|
2015
Q4 | – | Sell |
-353
| Closed | -$8K | – | 4485 |
|
|
2015
Q3 | $8K | Buy |
+353
| New | +$9.76K | ﹤0.01% | 2455 |
|
Other funds holding BPMC
IA
HNB
Tower Research Capital (TRC)'s BPMC Position: Q3 2025 in Review
Tower Research Capital (TRC) sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 6,527 shares — an estimated $837K sold.
Tower Research Capital (TRC) first reported a position in BPMC in Q3 2015 and held it in 32 quarters. The position peaked at $1.2M in Q2 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Tower Research Capital (TRC) reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 6,527 Blueprint Medicines shares in Q3 2025, an estimated $837K.
- Tower Research Capital (TRC) first reported a position in Blueprint Medicines in Q3 2015 and held it in 32 quarters.
- Tower Research Capital (TRC)'s Blueprint Medicines position peaked at $1.2M in Q2 2024.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.